Paper highlights Zabalafin Hydrogel's potential as a single topical atopic dermatitis therapy that impacts the Staphylococcus aureus component and treats all other disease symptoms across severity levels ANNAPOLIS, Md. , Nov. 1, 2024 /PRNewswire/ -- Alphyn Biologics, Inc.
, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics ® , announced today the publication of a peer-reviewed paper in the Journal of Drugs in Dermatology that highlights the potential of Zabalafin Hydrogel to manage the Staphylococcus aureus ( S. aureus )-driven mechanism behind atopic dermatitis (AD), as well as treat all the additional AD problems and severities, regardless of AD skin infection status. The paper, titled " A Consensus on Staphylococcus aureus Exacerbated Atopic Dermatitis and the Need for a Novel Treatment," underscores the importance of managing the S.
aureus -driven causes of AD, S. aureus -related AD exacerbation, and the S. aureus component in infected AD lesions to comprehensively treat AD.
The panel of six leading pediatric dermatologists who researched and authored the paper included Lawrence A. Schachner , MD., Mercedes E.
Gonzalez , MD, Karan Lal , DO, Adelaide A. Hebert , MD, Lawrence F. Eichenfield , MD, and Peter Lio , MD, with the assistance of Anneke Andriessen , Ph.
D. The group presented a consensus of five statements on S. aureus -driven AD exacerbation, challenges in current treatments for AD skin that is infected, and new developments t.
